BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22167411)

  • 1. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.
    Lagarde P; Pérot G; Kauffmann A; Brulard C; Dapremont V; Hostein I; Neuville A; Wozniak A; Sciot R; Schöffski P; Aurias A; Coindre JM; Debiec-Rychter M; Chibon F
    Clin Cancer Res; 2012 Feb; 18(3):826-38. PubMed ID: 22167411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
    Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
    Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
    Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
    J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
    Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
    Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors.
    Huang HY; Li SH; Yu SC; Chou FF; Tzeng CC; Hu TH; Uen YH; Tian YF; Wang YH; Fang FM; Huang WW; Wei YC; Wu JM; Li CF
    Clin Cancer Res; 2009 Nov; 15(22):6963-72. PubMed ID: 19887491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker.
    Yen CC; Yeh CN; Cheng CT; Jung SM; Huang SC; Chang TW; Jan YY; Tzeng CH; Chao TC; Chen YY; Yang CY; Ho CL; Fletcher JA
    Ann Surg Oncol; 2012 Oct; 19(11):3491-9. PubMed ID: 22588468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.
    Rege TA; Wagner AJ; Corless CL; Heinrich MC; Hornick JL
    Am J Surg Pathol; 2011 Apr; 35(4):495-504. PubMed ID: 21358303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
    Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
    Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
    Haller F; Schulten HJ; Armbrust T; Langer C; Gunawan B; Füzesi L
    Am J Surg Pathol; 2007 Jun; 31(6):933-7. PubMed ID: 17527083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs).
    Haller F; Löbke C; Ruschhaupt M; Cameron S; Schulten HJ; Schwager S; von Heydebreck A; Gunawan B; Langer C; Ramadori G; Sültmann H; Poustka A; Korf U; Füzesi L
    J Pathol; 2008 Jul; 215(3):253-62. PubMed ID: 18438954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
    Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
    Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct gene expression-defined classes of gastrointestinal stromal tumor.
    Yamaguchi U; Nakayama R; Honda K; Ichikawa H; Hasegawa T; Shitashige M; Ono M; Shoji A; Sakuma T; Kuwabara H; Shimada Y; Sasako M; Shimoda T; Kawai A; Hirohashi S; Yamada T
    J Clin Oncol; 2008 Sep; 26(25):4100-8. PubMed ID: 18757323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
    Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
    Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.
    Kang DY; Park CK; Choi JS; Jin SY; Kim HJ; Joo M; Kang MS; Moon WS; Yun KJ; Yu ES; Kang H; Kim KM
    Am J Surg Pathol; 2007 Feb; 31(2):224-32. PubMed ID: 17255767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Tzen CY; Wang MN; Mau BL
    Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors.
    Koelz M; Lense J; Wrba F; Scheffler M; Dienes HP; Odenthal M
    Int J Oncol; 2011 Feb; 38(2):503-11. PubMed ID: 21132270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.